Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Thoracic 2Other solid neoplasm 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 28Carcinoma, Non-Small-Cell Lung 8Triple Negative Breast Neoplasms 6Carcinoma, Renal Cell 4Pancreatic Neoplasms 3Neoplasm Metastasis 3Skin Neoplasms 2Sarcoma 2Mesothelioma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1

Interventions

aldesleukin 15pembrolizumab 11Cyclophosphamide 9fludarabine phosphate 7fludarabine 6Nivolumab 6Interleukin-2 6atezolizumab 5Radiotherapy 5Ipilimumab 4Interferon-alpha 4Drug Therapy 4Blood Specimen Collection 4Radiosurgery 3tremelimumab 2temsirolimus 2durvalumab 2cemiplimab 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Paclitaxel 2Metformin 2Interleukin-12 Subunit p35 2Genistein 2Gene Expression Profiling 2Flow Cytometry 2Filgrastim 2Cetuximab 2zanolimumab 1vivitrol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × spartalizumab × Dermatologic × Clear all
NCT02460224 2022-02-10

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Novartis

Phase 1/2 Completed
490 enrolled 77 charts
DermatologicGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Melanoma, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡